The quiet financialisation of biotech: How stablecoins are entering corporate treasury operations
Biotechnology has always been capital-intensive. Long research cycles, uncertain returns, and heavy funding requirements have historically defined how the sector manages money, cautiously, passively, with stability as the priority. That ...
